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Background: The widespread acceptance and application of 68Ga-PET depends on
our ability to develop radiopharmaceuticals that can be prepared in a convenient
and suitable manner. A kit-type labelling protocol provides such characteristics and
requires chelators that can be radiolabelled under exceptionally mild conditions.
Recently the DATA chelators have been introduced that fulfil these requirements. In
continuing their development, the synthesis and radiolabelling of the first DATA
bifunctional chelator (BFC) and peptide conjugate are described.
Results: A BFC derived from the DATA ligand (2,2’-(6-((carboxymethyl)amino)-1,4-
diazepane-1,4-diyl)diacetic acid) has been synthesised in five steps from simple
building blocks, with an overall yield of 8 %. DATAM5-3tBu (5-[1,4-Bis-tert-
butoxycarbonylmethyl-6-(tert-butoxycarbonylmethyl-methyl-amino)-[1, 4]diazepan-6-
yl]-pentanoic acid) has been coupled to [DPhe1][Tyr3]-octreotide (TOC) and the
resulting peptide conjugate (DATATOC) radiolabelled with purified 68Ga derived via
four different 68Ge/68Ga generator post-processing (PP) methods. The stability and
lipophilicity of the radiotracer have been assessed and a kit-type formulation for
radiolabelling evaluated. 68Ga-DATATOC has been prepared with a > 95 %
radiochemical yield (RCY) within 1 (fractionated and acetone-PP) and 10 min
(ethanol- and NaCl-PP) at 23 °C (pH 4.2–4.9, 13 nmol). The radiolabelled peptide is
stable in the presence of human serum. Lipophilicity of 68Ga-DATATOC was
calculated as logP = −3.2 ± 0.3, with a HPLC retention time (tR = 10.4 min) similar to
68Ga-DOTATOC (logP = −2.9 ± 0.4, tR = 10.3 min). Kit-type labelling from a lyophilised
solid using acetone-PP based labelling achieves > 95 % RCY in 10 min at 23 °C.
Conclusions: The favourable labelling properties of the DATA chelators have been
retained for DATATOC. High radiochemical purity can be achieved at 23 °C in less than
1 min and from a kit formulation. The speed, reliability, ease, flexibility and simplicity
with which 68Ga-DATATOC can be prepared makes it a very attractive alternative to
current standards.
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The positron emitter 68Ga has a number of characteristics which make it a very at-
tractive and promising radionuclide for PET imaging of disease and infection (Smith
et al. 2013; Fani et al. 2008). In spite of this and numerous publications which pro-
vide support for its superiority, more established radionuclides and imaging modal-
ities stand in its path (Buchmann et al. 2007; Tran et al. 2015). Interest in 68Ga-PET
in Europe has grown over the last years, highlighted by the recent promotion of
68Ga -DOTATATE and -DOTATOC to orphan drug status in the United States
(FDA Grants Orphan Drug Designation for 68Ga-DOTATOC. J Nucl Med 2014).
99mTc became the work-horse of nuclear medicine in part due to the development of
SPECT radiopharmaceuticals which can be prepared in a simple kit-type manner
(Roesch 2013). The development of chelators that permit a similar protocol for 68Ga
complement the inherent advantages of the 68Ge/68Ga-generator, paving the way for
realisation of its full potential and delivery of advanced imaging diagnostics world-
wide (Mukherjee et al. 2014; Velikyan et al. 2008).
The last decade of 68Ga-radiopharmaceutical chemistry has been dominated by stud-
ies with DOTATOC and its derivatives for the diagnosis of neuroendocrine tumours
(NETs) (Frilling et al. 2010). The omnipresence of DOTA derivatives in 68Ga-PET arose
from its success in other imaging applications (MRI and optical imaging with lantha-
nides) and its ability to provide an acceptable labelling profile and sufficient complex
stability with 68Ga (Notni et al. 2011; Boros et al. 2010). Optimisation of radiolabelling
protocols and the development of labelling modules have simplified radiopharmaceuti-
cal preparation, but the desire for further development remains (Ocak et al. 2010). The
major inherent disadvantage of DOTA derivatives is the relatively harsh conditions re-
quired for radiolabelling (80–95 °C, 5–10 min, pH 3–4) that impose a number of limi-
tations (Notni et al. 2011; Boros et al. 2010). Chelators which can be labelled quickly at
room temperature would simplify labelling further and offer the potential for kit-type
labelling akin to the prestigious 99mTc kits. Temperature/pH sensitive targeting vectors
(TVs) would benefit from these new chelators in particular, and widen the portfolio of
68Ga-based diagnostics. In recent times, there has been greater focus on the develop-
ment of more efficient hexadentate chelators, and bifunctional derivatives of NOTA,
TRAP, NOPO, DEDPA, CP256, HBED have been described that chelate 68Ga(III) rap-
idly at room temperature (Notni et al. 2011; Fani et al. 2012; Simeček et al. 2012; Boros
et al. 2012; Berry et al. 2011; Eder et al. 2008).
The potential for kit-type labelling of biomolecule conjugates has been alluded to on
numerous occasions, but a protocol which can achieve acceptable yields from a lyophi-
lised solid at ambient temperature remains ‘the final frontier’ (Mukherjee et al. 2014;
Velikyan et al. 2008 Asti et al. 2015; Waengler et al. 2011). The DATA chelators rapidly
form stable complexes with 68Ga under exceptionally mild conditions befitting kit-type
labelling (Waldron et al. 2013; Parker & Waldron 2013; Parker et al. 2013). The ligand
DATAM (Fig. 1) for instance, can enable radiochemical yields (RCYs) greater than 97 %
at 23 °C in under 1 min (Seemann et al. 2015a). Earlier work showed that it is pos-
sible to label DATA chelators over the pH range 4–7, however for the purposes of
this work it was decided that only optimum labelling conditions would be used in
line with the desire to develop a room temperature kit-type labelling protocol
(Waldron et al. 2013; Seemann et al. 2015a).
Fig. 1 DATAM, bifunctional prochelator DATAM5-3tBu and DATATOC (left to right)
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conjugate towards development of kit-type labelling in a setting that holds considerable
practical interest. The peptide TOC has been extensively studied with other chelators
(DOTA, NODAGA, DTPA, DFO) in both imaging and therapeutic modalities, and has
significant clinical and commercial importance (Lin et al. 2013; Eisenwiener et al. 2002;
Dumont et al. 2011; Fani et al. 2011; Ugur et al. 2002). Hence, DATA conjugates were
envisaged to allow comparative analysis.
The first step was to develop and synthesise a novel DATA bifunctional prochelator
(DATAM5-3tBu) that permits convenient amide conjugation to the N-terminus of TOC.
A bifunctional derivative of DATAM has been synthesised and conjugated to protected
TOC using standard methods (Fig. 1). An initial radiolabelling evaluation of the conju-
gate (DATATOC, Fig. 1) has been carried out at ambient temperature, and a kit-type
formulation tested.Methods
Reagents were purchased from Sigma-Aldrich® or Merck® and used without further
purification. Purite® water used was filtered through a Millex® Millipore filter membrane
(0.54 μm). Reaction progress was monitored using silica TLC-plates (silica 60 F254
4.5 × 4.5 cm, Merck) and visualised with UV254nm and/or KMnO4. Column chromatog-
raphy was performed with silica gel 60 (Fisher Scientific®; 0.04–0.063 nm). NMR spec-
tra (1H, 13C, HSQC, HMBC) were recorded on an Avance III HD 400 (Bruker, United
States). Chemical shifts are given in ppm. MS (ESI) were performed with a Thermo Quest
Navigator Instrument (Thermo Electron). Mass spec results are given as m/z in g/mol.
HPLC was performed with a metal-free Dionex ICS-5000 system with a quaternary pump,
an AS-50 auto sampler, UV/vis detector and automated fraction collector AFC-3000.Synthesis
The chemical identity of synthesised compounds has been confirmed by 1H-, 13C-NMR
and HR MS with the exception of TOC conjugates, which have been characterised by
HPLC and HRMS. 1H-, 13C-NMR and HRMS data for compounds prior to TOC conju-
gation are provided in the S.I. (Fig. 2).
5-(1,4-Dibenzyl-6-nitro-[1, 4]diazepan-6-yl)-pentanoic acid methyl ester (1) 2-
Nitrocyclohexanone (0.608 g, 4.3 mmol) was added to Amberlyst A21 (1.216 g, 2 mass
equivalents) in EtOH and stirred for 2 h at 60 °C under argon. N,N′-Dibenzyl-ethylene-
diamine (1.020 g, 4.3 mmol) and paraformaldehyde (0.446 g, 14.9 mmol) were added
and the reaction stirred at 60 °C overnight. The mixture was filtered through Celite®,
Fig. 2 Synthesis of the unconjugated DATA prochelator - DATAM5-3tBu. (i) Amberlyst-21, EtOH; (ii) CH2O, EtOH;
(iii) CH3COOH, Pd(OH)2/C, H2, EtOH; (iv) BrCH2COO
tBu, K2CO3, MeCN; (v) CH3I, K2CO3, DCM : MeCN; (vi) LiOH,
THF : H2O
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CHCl3 (40 mL) and washed successively with aqueous K2CO3 solution (2 × 30 mL,
0.1 M) and H2O (30 mL), dried over MgSO4, filtered and solvent removed under re-
duced pressure. Purification by silica gel column chromatography (DCM) afforded the
title compound as a yellow oil (1.607 g, 85 %). Rf = 0.80 (DCM).
5-(1,4-Dibenzyl-6-nitro-[1,4]diazepan-6-yl)-pentanoic acid methyl ester (2) A catalytic
amount of Pd(OH)2/C and acetic acid (50 μL, 0.87 mmol) was added to the protected
triamine 1 (0.10 g, 0.29 mmol) in MeOH (20 mL), and the mixture agitated under an
atmosphere of hydrogen for 3 h (1 atm H2). TLC (DCM) was used to confirm complete
reduction of the nitro group and cleavage of the benzyl N-substituents. Pd(OH)2/C was
removed using a Celite® filter. The solvent was removed under reduced pressure to af-
ford a yellow oil. (0.065 g, 97 %)
5-[1,4-Bis-tert-butoxycarbonylmethyl-6-(tert-butoxycarbonylmethyl-amino)-[1,4]diaze-
pan-6-yl]-pentanoic acid methyl ester (3) tert-Butyl-bromoacetate (0.567 g, 2.91 mmol)
was added to 2 (0.208 g, 0.91 mmol) and K2CO3 (0.377 g, 2.73 mmol) in MeCN
(25 mL), and the mixture stirred for 24 h at 368 K under an atmosphere of argon. The
reaction was monitored by TLC (hexane/ethyl acetate; 1:1) for formation of the tetra-
alkylated derivative. The solvent was removed under reduced pressure, and the
resulting oil re-dissolved in CHCl3 (25 mL) and washed successively with aqueous
K2CO3 solution (2 × 25 mL, 0.1 M) and H2O (25 mL), dried over MgSO4, filtered and
solvent removed under reduced pressure. Purification by silica gel column chroma-
tography (hexane/ethyl acetate, 2:1 → 1:1) afforded a yellow oil (0.229 g, 44 %). Rf =
0.35 (hexane/ethyl acetate; 2:1).
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[1,4]diazepan-6-yl]-pentanoic acid methyl ester (4) Iodomethane (0.023 g, 0.16 mmol)
was added to 3 (0.104 g, 0.18 mmol) and K2CO3 (0.025 g, 0.18 mmol) in DCM/MeCN
(3:1) cooled in an ice-bath. The reaction mixture was allowed to warm to room
temperature and left overnight. The solvent was removed under reduced pressure and
the resulting oil re-dissolved in CHCl3 (20 mL), filtered, and washed successively with
aqueous K2CO3 solution (2 × 20 mL, 0.1 M) and H2O (20 mL), dried over MgSO4, fil-
tered and solvent removed under reduced pressure. Purification by silica gel column
chromatography (hexane/ethyl acetate, 3:1 → 2:1) afforded a yellow oil (0.043 g, 46 %).
Rf = 0.38 (hexane/ethyl acetate; 2:1).
5-[1,4-Bis-tert-butoxycarbonylmethyl-6-(tert-butoxycarbonylmethyl-methyl-amino)-
[1,4]diazepan-6-yl]-pentanoic acid (5) LiOH (0.009 g, 0.039 mmol) dissolved in H2O
(0.5 mL) was added to 4 (0.010 g, 0.023 mmol) in THF (0.5 mL), and the mixture
stirred at 298 K. The reaction was monitored using LC-ESI MS for ester cleavage. Once
complete, the solvent was removed by lyophilisation. H2O (5 mL) was added and re-
moved by lyophilisation, and the procedure repeated two more times. The resulting
solid was washed with ice-cold DCM (0.5 mL), and dried in vacuo to afford a waxy yel-
low solid (0.009 g, 70 %).Synthesis of DATATOC
Commercially available protected TOC [(D)Phe1,Tyr(tBu)3,D-Trp(Boc)4,Lys(Boc)5,
Thr(tBu)6,8]-octreotide was coupled to 5 using N,N-diisopropylethylamine (DIPEA) and
O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU).
The protected TOC (0.024 g, 0.017 mmol), HBTU (0.0010 g, 0.029 mmol), DIPEA
(0.0016 g, 0.12 mmol) and 5 (0.015 g, 0.026 mmol) were added to dry DMSO (2 mL)
and stirred at ambient temperature for 4 h. The solvent was removed under reduced
pressure, and the resulting residue dissolved in 1 mL MeCN. The precipitate was re-
moved by centrifugation, and solvent removed by lyophilisation. The resulting oil was
purified by HPLC (C18-RP; A = 0.1 % TFA in H2O; B =MeCN; 0–2 min 35 % A; linear
gradient to 10 % A at 14 min, 14–24 min 10 % A). The fully protected product (6)
eluted with a retention time of 21 min (0.014 g, 41 %). MS ES+ (m/z) found: 1957.1133
[M +H]+; C100H158N13O22S2 calcd for: 1957.1086.
Deprotecting of the chelator and TOC was performed by dissolving 6 (0.050 g, 2.6 × 10−5
mmol) in a mixture of TFA/water/triisopropylsilane (95:2.5:2.5) and stirring at ambient
temperature overnight. Once complete, the solvent was removed by lyophilisation. H2O/
MeCN (1 mL, 1:1) was added and removed by lyophilisation, and the procedure repeated
two more times. Purification was performed by preparative HPLC (C18-RP; A = 0.1 % TFA
in water and B =MeCN; linear gradient: 0 min 80 % A, 15 min 65 % A, tR (product) =
12 min). DATATOC was eluted with a retention time of 12 min (0.006 g, 76 %). HR MS
ES+ (m/z) found: 1421.6259 [M+H]+; calcd. for C66H94N13O18S2: 1420.6281 (Fig. 3).Radiochemistry
All radiochemical evaluations were conducted using chemicals of the highest available
purity grade. Volumes were measured using an Eppendorf pipette. A TiO2-based
68Ge/
68Ga generator (Cyclotron Co., Obninsk, Russia) was used for all radiochemical
Fig. 3 Synthesis of DATATOC
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concentrate the radioactive eluate: fractionation, acetone-, ethanol- and NaCl-based.
Procedures were carried out, and solutions required prepared, as detailed in the rele-
vant publication (Zhernosekov et al. 2007; Mueller et al. 2012; Eppard et al. 2014;
Breeman et al. 2005). pH was measured using a Mettler-Toledo, SevenEasy pH. Radio-
TLC was performed using silica-60 TLC plates (Merck F254, 4.5 × 4.5 cm), and eluted
using 0.1 M citrate buffer (pH 4). Eluted radio-TLC plates were analysed using a
flat-bed imaging scanner (Instant Imager, Canberra Packard).Radiolabelling
Experiments were carried out in triplicate, and the amount of DATATOC used was
constant in each case (13 nmol) taken from a 1 mg/mL stock solution. The volume of
eluate differed according to the post-processing used, but was diluted as necessary so
that ~ 100 MBq 68Ga was used for radiolabelling in each instance. Radiolabelling exper-
iments were maintained at 23 °C by means of a heater-shaker device (DITABIS MHR
11), which was also used to agitate (400 rpm) radiolabelling solutions. TLC samples
(1 μL) were taken at 1, 3, 5 and 10 min. The optimised labelling conditions vary ac-
cording to the PP method applied. The important differences and approach used in
each case are summarised in Table 1.
Table 1 Key features of the radiolabelling procedures used
PP method Eluate volume (mL) Labelling media Buffer volume (mL) DATATOC (nmol/μM) Labelling pH
Fractionation 0.900 1.00 M NH4OAc 0.200 13 / 11.8 4.9
Acetone 0.400 0.20 M NaOAc 1.000 13 / 9.29 4.5
Ethanol 1.000 1.00 M NH4OAc 1.500 13 / 5.20 4.9
NaCl 0.510 1.00 M NH4OAc 3.500 13 / 3.24 4.2
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Stability was assessed following formation of 68Ga-DATATOC using ethanol-PP 68Ga
and performed in triplicate. The stability was assessed by incubating 68Ga-DATATOC
(50 μL) in an excess of human serum (300 μL) at 37 °C and pH 7 (1.0 M phosphate
buffered saline) for 2 h. Samples (1 μL) were taken at 30, 60, 90 and 120 min and ana-
lysed by radio-TLC.Lipophilicity of 68Ga-DATATOC
The lipophilicity was determined using the shake-flask method (logP) and qualitatively
by radio-HPLC relative to 68Ga-DOTATOC (Notni et al. 2013; Du et al. 1998). Radiola-
bels were prepared following acetone-PP. Analytical radio-HPLC (LiChrospher 100-RP-
18EC, 1 mL/min) for lipophilicity studies was based on a gradient using H2O (A) and
MeCN (B), each containing 0.1 % TFA. Mobile phase gradient: 0–1.5 min 1 % B, 1.5–
10.5 min 99 % B, 11.5 min 99 % B, 12–15 min 1 % B. The HPLC was coupled to a UV
(Hitachi L-7400) and a radioactivity (Gamma Raytest) detection system. HPLC grade
solvents were used and degassed by sonication for 15–20 min prior to use.Kit-type labelling
Formulations for labelling following fractionation and acetone-PP were used to investi-
gate the possibility of kit-type labelling.
Acetone-PP: The precursor solution was prepared as per Table 1 and lyophilised into
a vial suitable for labelling. The post-processed 68Ga was diluted to the labelling volume
(1.4 mL) using H2O and added to the lyophilised solid. The mixture was agitated on a
test-tube vortex for 2 s and left to stand at ambient temperature.
Fractionated 68Ga: owing to the nature of the labelling media used, it was not pos-
sible to prepare a lyophilised solid. After addition of 68Ga, the labelling solution was ag-
itated on a test-tube vortex for 2 s and left to stand at ambient temperature. After
10 min a 1 μL sample was extracted and analysed by radio-TLC.Results
Cold-Synthesis
The synthesis of DATAM5-3tBu was successfully carried out in five-steps in an 8 %
yield. A further two steps were required to afford DATATOC in a yield of 31 %.Radiochemical evaluations
The optimised labelling of DATATOC using 68Ga PP by four common procedures is
shown in Fig. 4. The labelling volume varies depending on the PP method used, and as

















Acetone PP NaCl PP
Fig. 4 Time dependent labelling for the formation of 68Ga-DATATOC using 68Ga post-processed by
fractionation, acetone-, ethanol- and NaCl-based procedures
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eluate within 10 min, and from a kit formulation. Radio-HPLC confirmed that the radi-
olabelled product was the same in each instance.
In human serum 98.7 % of the initially present 68Ga-DATATOC remained intact after
2 h. The lipophilicity of 68Ga-DATATOC and 68Ga-DOTATOC, determined using the
shake-flask method, are logP = −3.22 ± 0.32 and −2.93 ± 0.37 respectively. The respect-
ive retention times from radio-HPLC are 10.4 and 10.3 min.
Discussion
The synthesis of DATAM5-3tBu followed the same synthetic pathway as that of
DATAM, with the only modification being the type of reagent used in the first step. A
similar synthetic route was reported for an AAZTA conjugate with the same linker
functionality, and the product labelled with 68Ga (Manzoni et al. 2012). In our experi-
ence, the heptadentate AAZTA ligand itself is unsuitable for chelation of 68Ga due to
the formation of multiple radiolabelled species (Baranyai et al. 2009). The spacer and
linker moieties for conjugation are incorporated in the first step during formation of
the 7-membered diazepine ring. A five-carbon spacer, attached to the quaternary car-
bon of the ring, possesses an acid which is orthogonally protected as an ester relative
to the chelating acids, to ensure selective conjugation of TOC. The key step is the N-
methylation (step 4), necessary to prevent an internal cyclisation with an adjacent acet-
ate, where care is required to prevent formation of a quaternary amine. A suitably pro-
tected TOC derivative was conjugated in solution, with subsequent deprotecting of the
chelator and peptide occurring simultaneously.
There are four commonly used 68Ga generators and four main PP methods (acetone-,
ethanol-, NaCl- based and fractionation) (Zhernosekov et al. 2007; Mueller et al. 2012;
Eppard et al. 2014; Breeman et al. 2005). Each generator and PP method has particular
advantages and the combination used varies from group to group. This variety adds a
layer of complication because the optimum labelling conditions and labelling efficiency
of a given precursor can vary depending on the combination applied (Seemann et al.
2015a). A precursor which can be labelled reliably using any combination of the
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tween institutions. The labelling experiments have been performed using an Obninsk
(EZAG) generator eluted with 0.1 M HCl. The setup is intended to serve as an example
to demonstrate the versatility of labelling procedures which can be applied to DATA-
TOC. Further validation of any kit-type labelling protocol requires implementation with
a market authorised 68Ga-generator. Radiolabelling of DATATOC was evaluated at am-
bient temperature using 68Ga PP by each of the four methods, optimised in terms of
the labelling pH. Remarkably, RCYs > 95 % were achieved in only 1 min with fraction-
ated and acetone-PP 68Ga, and > 98 % in 10 min regardless of the PP method applied.
The precursor concentration increases along the series NaCl-, ethanol-, acetone- and
fractionation PP, and is most likely the reason for the increasing rate of labelling
along the same series. According to European Pharmacopeia governing 68Ga-DOTA-
TOC a radiochemical purity of at least 91 % is required (measured by HPLC and
TLC) prior to in vivo administration, which may require the inclusion of a post-
labelling purification (Virgolini et al. 2010). Based on the results gathered such a pro-
cedure to improve the RCY is redundant for the preparation of 68Ga-DATATOC. This
is analogous to the very successful 99mTc-kits and not only simplifies the process but
also saves time – a valuable commodity considering the short half-life of 68Ga com-
pared to 99mTc and 18F.
The influence of lower precursor concentrations has not been tested, but based on
the radiolabelling profile it is apparent that there is scope for reduction. Nevertheless,
the concentration used compares well with other 68Ga-labelled peptide preparations
(Notni et al. 2011; Berry et al. 2011; Lin et al. 2013; Eisenwiener et al. 2002; Dumont
et al. 2011; Fani et al. 2011; Ugur et al. 2002; Virgolini et al. 2010; Wester et al. 1997).
Based on the results it is evident that the favourable properties of the original DATAM
chelator have not been negatively affected to any significant extent by conjugation to
TOC. Surprisingly, with NaCl- and ethanol-PP 68Ga, DATATOC shows superior label-
ling kinetics to the unfunctionalised chelator – DATAM (Seemann et al. 2015b).
There is no evidence for radiolysis of 68Ga-DATATOC on radio-HPLC following la-
belling. In human serum there was no appreciable release of 68Ga over 2 h, indicating a
high metabolic and kinetic stability (98.7 %).
The relative lipophilicities 68Ga-DATATOC and 68Ga-DOTATOC determined by
radio-HPLC and shake-flask methods are consistent and show that the former is mar-
ginally more lipophilic. Publications involving 68Ga-labelled TOC with different chela-
tors have highlighted the importance of the chelator in terms of in vivo performance,
suggesting that the BFC could be tailored to the TV used (Lin et al. 2013; Eisenwiener
et al. 2002; Dumont et al. 2011; Fani et al. 2011; Ugur et al. 2002; Wester et al. 1997).
Previous work has shown that is possible to modify the lipophilicity of DATA chelators
without disturbing the radiolabelling characteristics, offering the potential to look at
this relationship more closely (Seemann et al. 2015b).
The feasibility of a kit-type formulation has been assessed using fractionated and
acetone-PP 68Ga and produced excellent results. Virtually quantitative yields were ob-
tained in less than 10 min (shorter intervals not analysed) from a lyophilised solid for-
mulation with acetone-PP 68Ga. A similar result was achieved with fractionated 68Ga
(97 % RCY). However, it was not possible to lyophilise the precursor formulation due
to the tendency of ammonia acetate to sublime under the reduced pressure required to
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quired for labelling is incorporated into the water used to dilute activity prior to label-
ling rather than as part of the lyophilised solid.
To the best of our knowledge, this is the first example of a 68Ga- radiopharma-
ceutical that can be prepared from a lyophilised solid at ambient temperature in less than
10 min. There are examples of 68Ga kits requiring elevated temperatures, but we are only
aware of a single ambient temperature kit where labelling of a NOTA-peptide conjugate
occurred from a pre-dissolved formulation (Mukherjee et al. 2014; Velikyan et al. 2008).
Beyond the development of kit-type formulations, these favourable characteristics can also
be exploited through the development of previously inaccessible temperature sensitive
biomolecules.
It could be argued that the PP procedures currently available do not compliment
the advantages of kit-type labelling because they are manual procedures with a se-
quence of steps. At this stage this part of the manufacturing process then does not corres-
pond to a kit-type preparation. However, the PP protocols are still simple and routine such
that there remains substantial benefits to a very simple, fast and reliable labelling method.
Future improvements to the generator and elution procedures may lend themselves better
to kit-type labelling, but in the meantime there are sophisticated modules capable of post-
processing the eluate with minimal input from the user which would benefit from kit-type
labelling.Conclusion
The first DATA bifunctional chelator has been synthesised and conjugated to TOC in a
short seven-step synthesis using affordable starting materials. DATATOC displays re-
markable radiolabelling characteristics with > 95 % RCYs possible within 1 min at ambi-
ent temperature (pH 4.9, 13 nmol) providing a radiotracer with high human serum
stability. 68Ga-DATATOC can be efficiently prepared using 68Ga post-processed by the
full range of commonly used methods. The labelling protocols are facile, reliable, robust
and do not require non-standard equipment and reagents. Initial efforts towards the
development of a kit-type formulation analogous to 99mTc have been successful, and
are now being shared with other research groups to assess performance in different set-
tings. In vivo and in vitro studies comparing 68Ga-labelled DATATOC, DOTATOC and
NODAGATOC are underway.
68Ga-DATA conjugated radiopharmaceuticals may meet the five main definitions of
kit-like preparations: A radiopharmaceutical which can be prepared in a (i) sufficient
radiochemical yield (ii) from a lyophilised solid (iii) at room temperature (iv) within a
short time (v) that does not require post-labelling purification to meet pharmacopeia
standards. The radiochemical performance of DATATOC highlights the potential of
DATA-conjugates to carry 68Ga-PET into widespread application through the availabil-
ity of a true ‘kit-type’ formulation, a facile and cost effective synthesis as well as the
preparation of previously inaccessible radiotracers.Ethical approval
This article does not contain any studies with human participants or animals performed
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Additional file 1: Figure S1. RadioTLC for kit-type 68Ga-labelling of DATATOC at 1, 3, 5, 10 and 15 min. Figure S2:
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